Jarosław Kaźmierczak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jarosław Kaźmierczak has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Aldona Siennicka
Department of Medical Analytics, Pomeranian Medical University, 70-111 Szczecin, Poland
2 shared publications - Dominika Maciejewska
Department of Human Nutrition and Metabolomics, Pomeranian Medical University in Szczecin, Broniewskiego 24, 71-460 Szczecin, Poland
2 shared publications - Natalia Jakubiak
Department of Human Nutrition and Metabolomics, Pomeranian Medical University in Szczecin, Broniewskiego 24, 71-460 Szczecin, Poland
2 shared publications - Radosław Kiedrowicz
Department of Cardiology, Pomeranian Medical University, 70-111 Szczecin, Poland
2 shared publications - Aleksandra Kładna
Department of the History of Medicine and Medical Ethics, Pomeranian Medical University, ul. Rybacka 1, 70-204 Szczecin, Poland
1 shared publication - Aleksandra Szylińska
Department of Cardiac Surgery, Pomeranian Medical University in Szczecin, 70-111 Szczecin, Poland
1 shared publication
Latest Publications
- Open Access
- 22 October 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (21) , 7456
Superior Vena Cava as an Arrhythmogenic Substrate in Atrial Fibrillation: Anatomical, Electrophysiological and Clinical Perspectives
Catheter ablation is an established treatment method for atrial fibrillation. In most cases, the arrhythmia substrate is located within the pulmonary veins and their isolation has become the cornerstone of catheter ablation therapy. However, it is estimated that in 10–20% of patients, the trigger and/or sustaining factors for the arrhythmia are located outside the pulmonary veins. This is particularly relevant in patients with significant disease progression and persistent forms of AF, where these sites are likely responsible for treatment failure and arrhythmia recurrence. Identifying non-pulmonary vein triggers of AF and understanding their impact on disease progression is crucial but remains insufficiently explored. Gaining such insights offers hope for optimizing treatment strategies and improving outcomes for patients. The most commonly mentioned ectopic arrhythmogenic focus include the superior vena cava (SVC). Despite its clinical significance in arrhythmogenesis, the detailed electrophysiological properties of the SVC have received relatively limited research attention compared to other cardiac structures. Moreover, scientific papers that present extensive knowledge on SVC- from its embryology to the electrophysiology scarce. Therefore we would like to offer a comprehensive analysis of existing literature concerning SVC as an arrhythmogenic substrate for AF.
- 22 October 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (21) , 7456
Open AccessSuperior Vena Cava as an Arrhythmogenic Substrate in Atrial Fibrillation: Anatomical, Electrophysiological and Clinical Perspectives
Catheter ablation is an established treatment method for atrial fibrillation. In most cases, the arrhythmia substrate is located within the pulmonary veins and their isolation has become the cornerstone of catheter ablation therapy. However, it is estimated that in 10–20% of patients, the trigger and/or sustaining factors for the arrhythmia are located outside the pulmonary veins. This is particularly relevant in patients with significant disease progression and persistent forms of AF, where these sites are likely responsible for treatment failure and arrhythmia recurrence. Identifying non-pulmonary vein triggers of AF and understanding their impact on disease progression is crucial but remains insufficiently explored. Gaining such insights offers hope for optimizing treatment strategies and improving outcomes for patients. The most commonly mentioned ectopic arrhythmogenic focus include the superior vena cava (SVC). Despite its clinical significance in arrhythmogenesis, the detailed electrophysiological properties of the SVC have received relatively limited research attention compared to other cardiac structures. Moreover, scientific papers that present extensive knowledge on SVC- from its embryology to the electrophysiology scarce. Therefore we would like to offer a comprehensive analysis of existing literature concerning SVC as an arrhythmogenic substrate for AF.
- Open Access
- 3 September 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (17) , 6216
Serum Zonulin and Lipopolysaccharide (LPS) Levels in Early Myocardial Infarction: Association with Left Ventricular Ejection Fraction
Background: Atherosclerosis is the main cause of coronary heart disease, which frequently precedes the onset of heart failure. Lipopolysaccharide (LPS), a pro-inflammatory endotoxin produced by Gram-negative bacteria, exacerbates atherosclerotic processes and negatively impacts myocardial function, particularly in the context of activating low grade inflammation. Zonulin, a key regulator of the blood-gut barrier, modulates tight junction permeability, potentially facilitating the translocation of microbial-derived compounds, including LPS, into the circulation. Given these interactions, we investigated serum levels of lipopolysaccharide and zonulin in patients following myocardial infarction. This study aimed to assess serum levels of zonulin and lipopolysaccharide (LPS) in patients who had experienced a myocardial infarction (MI) and to evaluate the association between these biomarkers and ejection fraction (EF) across different patient groups. Methods: 78 patients (22 women and 56 men) diagnosed with MI, who underwent primary PCI (percutaneous coronary intervention), were included in the study. The blood samples were collected between 24 and 48 h after PCI. Results: Post-myocardial infarction patients with an ejection fraction ≤ 40% exhibited significantly elevated serum lipopolysaccharide levels compared to those with an ejection fraction > 40%. However, no significant differences in zonulin levels were observed between the study groups. Conclusions: Our findings suggest that elevated serum lipopolysaccharide levels may be associated with a reduction in post-infarction ejection fraction. This observation highlights a potential link between endotoxemia and impaired myocardial function following MI, warranting further investigation.
- 3 September 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (17) , 6216
Open AccessSerum Zonulin and Lipopolysaccharide (LPS) Levels in Early Myocardial Infarction: Association with Left Ventricular Ejection Fraction
Background: Atherosclerosis is the main cause of coronary heart disease, which frequently precedes the onset of heart failure. Lipopolysaccharide (LPS), a pro-inflammatory endotoxin produced by Gram-negative bacteria, exacerbates atherosclerotic processes and negatively impacts myocardial function, particularly in the context of activating low grade inflammation. Zonulin, a key regulator of the blood-gut barrier, modulates tight junction permeability, potentially facilitating the translocation of microbial-derived compounds, including LPS, into the circulation. Given these interactions, we investigated serum levels of lipopolysaccharide and zonulin in patients following myocardial infarction. This study aimed to assess serum levels of zonulin and lipopolysaccharide (LPS) in patients who had experienced a myocardial infarction (MI) and to evaluate the association between these biomarkers and ejection fraction (EF) across different patient groups. Methods: 78 patients (22 women and 56 men) diagnosed with MI, who underwent primary PCI (percutaneous coronary intervention), were included in the study. The blood samples were collected between 24 and 48 h after PCI. Results: Post-myocardial infarction patients with an ejection fraction ≤ 40% exhibited significantly elevated serum lipopolysaccharide levels compared to those with an ejection fraction > 40%. However, no significant differences in zonulin levels were observed between the study groups. Conclusions: Our findings suggest that elevated serum lipopolysaccharide levels may be associated with a reduction in post-infarction ejection fraction. This observation highlights a potential link between endotoxemia and impaired myocardial function following MI, warranting further investigation.
- Open Access
Assessment of the Effectiveness of Fascial Manipulation in Patients with Degenerative Disc Disease of the Lumbosacral Spine
Background: The aim of this study was to evaluate the effectiveness of Fascial Manipulation in patients with disc herniations of the lumbar spine confirmed by magnetic resonance imaging. Material and Methods: This study included 69 patients with intervertebral disc damage of the lumbar spine, as confirmed by magnetic resonance imaging. Patients were divided into two groups: a study group and a control group. The control group (C) was treated conservatively with treatments such as interference currents, diadynamic currents, tens currents, galvanization, Sollux lamps, local cryotherapy, magnetic fields, therapeutic massages of the spine, and mobility exercises. The study group (S) was subjected to therapy using Fascial Manipulation, which included two treatments—the first on the day the patient reported for the study and the second a week later. Patients for this study were selected at random. Results: This study presents a statistically significant difference between the treatment effects, as assessed by the degree of pain (p < 0.001) and mobility limitation (p < 0.001), as well as the presence of stretch symptoms (p < 0.001): all three parameters improved significantly more in the study group compared to the control group. Conclusion: Fascial Manipulation is an effective method for treating pain in patients with disc herniations of the lumbar spine; in addition to reducing pain, it improves the range of motion and the results of SLR and PKB tests. In lumbar spine pain in disc herniations, treatment using Fascial Manipulation is definitely more effective than treatment according to the traditional physiotherapy regimen.
Open AccessAssessment of the Effectiveness of Fascial Manipulation in Patients with Degenerative Disc Disease of the Lumbosacral Spine
Background: The aim of this study was to evaluate the effectiveness of Fascial Manipulation in patients with disc herniations of the lumbar spine confirmed by magnetic resonance imaging. Material and Methods: This study included 69 patients with intervertebral disc damage of the lumbar spine, as confirmed by magnetic resonance imaging. Patients were divided into two groups: a study group and a control group. The control group (C) was treated conservatively with treatments such as interference currents, diadynamic currents, tens currents, galvanization, Sollux lamps, local cryotherapy, magnetic fields, therapeutic massages of the spine, and mobility exercises. The study group (S) was subjected to therapy using Fascial Manipulation, which included two treatments—the first on the day the patient reported for the study and the second a week later. Patients for this study were selected at random. Results: This study presents a statistically significant difference between the treatment effects, as assessed by the degree of pain (p < 0.001) and mobility limitation (p < 0.001), as well as the presence of stretch symptoms (p < 0.001): all three parameters improved significantly more in the study group compared to the control group. Conclusion: Fascial Manipulation is an effective method for treating pain in patients with disc herniations of the lumbar spine; in addition to reducing pain, it improves the range of motion and the results of SLR and PKB tests. In lumbar spine pain in disc herniations, treatment using Fascial Manipulation is definitely more effective than treatment according to the traditional physiotherapy regimen.
- Open Access
- 6 December 2024
- Published by MDPI AG in Metabolites
- Vol. 14 (12) , 686
Calcitriol Concentration in the Early Phase of Myocardial Infarction and Its Relation to Left Ventricular Ejection Fraction
Vitamin D deficiency is one of the most common metabolic disorders in the European population. A low level of 25-OH vitamin D3 is related to an elevated risk of myocardial infarction (MI). The aim of our study was to examine the relationship between calcidiol and calcitriol serum concentration and left ventricular ejection fraction early after interventional treatment for acute coronary syndrome. A total of 80 patients diagnosed with MI, who underwent primary percutaneous coronary intervention, were included in the study. Blood samples for calcidiol, calcitriol, and vitamin D-binding protein were obtained 24 h after primary PCI and were measured using an enzyme-linked immunosorbent assay. Only 9% of patients had a proper level of 25-OHD3 in the serum (30–80 ng/mL). A total of 16% of patients revealed a suboptimal concentration of 25-OHD3 (20–30 ng/mL), and in 75% of patients, the concentration of 25-OHD3 was lower than 20 ng/mL. Moreover, patients with left ventricle ejection fraction of <40% had significantly lower concentrations of calcidiol and calcitriol. A low calcitriol serum concentration affects post-MI left ventricle ejection fraction early after myocardial infarction onset. It seems that 1.25(OH)D3 may contribute to acute myocardial infarction; however, there are insufficient clinical trials related to this topic, and the available evidence is mainly from in vitro studies. We hope these preliminary reports will provide a better understanding of post-MI.
- 6 December 2024
- Published by MDPI AG in Metabolites
- Vol. 14 (12) , 686
Open AccessCalcitriol Concentration in the Early Phase of Myocardial Infarction and Its Relation to Left Ventricular Ejection Fraction
Vitamin D deficiency is one of the most common metabolic disorders in the European population. A low level of 25-OH vitamin D3 is related to an elevated risk of myocardial infarction (MI). The aim of our study was to examine the relationship between calcidiol and calcitriol serum concentration and left ventricular ejection fraction early after interventional treatment for acute coronary syndrome. A total of 80 patients diagnosed with MI, who underwent primary percutaneous coronary intervention, were included in the study. Blood samples for calcidiol, calcitriol, and vitamin D-binding protein were obtained 24 h after primary PCI and were measured using an enzyme-linked immunosorbent assay. Only 9% of patients had a proper level of 25-OHD3 in the serum (30–80 ng/mL). A total of 16% of patients revealed a suboptimal concentration of 25-OHD3 (20–30 ng/mL), and in 75% of patients, the concentration of 25-OHD3 was lower than 20 ng/mL. Moreover, patients with left ventricle ejection fraction of <40% had significantly lower concentrations of calcidiol and calcitriol. A low calcitriol serum concentration affects post-MI left ventricle ejection fraction early after myocardial infarction onset. It seems that 1.25(OH)D3 may contribute to acute myocardial infarction; however, there are insufficient clinical trials related to this topic, and the available evidence is mainly from in vitro studies. We hope these preliminary reports will provide a better understanding of post-MI.